

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): January 18, 2008**

**OPKO Health, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or other  
jurisdiction of  
incorporation)

**000-26648**  
(Commission  
File Number)

**75-2402409**  
(IRS Employer  
Identification No.)

**4400 Biscayne Blvd**  
**Suite 1180**  
**Miami, Florida 33137**  
(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (305) 575-4138

\_\_\_\_\_  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 5.02.       Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;  
Compensatory Arrangements of Certain Officers.**

On January 18, 2008, David Eichler resigned as a member of the Board of Directors of OPKO Health, Inc. (the “Company”). The resignation of Mr. Eichler did not involve any disagreement with the Company. Effective as of January 24, 2008, Richard C. Pfenniger, Jr. was appointed as a director of the Company to fill the vacancy created by Mr. Eichler’s resignation. Mr. Pfenniger was also appointed to serve as Chairman of the Company’s Audit Committee.

Effective January 24, 2008, the Board also voted to increase the size of the Board from nine to ten directors, and the Board appointed Thomas E. Beier to fill the additional seat created on the Board. Mr. Beier was appointed to serve on the Company’s Audit Committee and the Compensation Committee.

**ITEM 9.01.       Financial Statements and Exhibits.**

(d) Exhibits

99.1   Press Release dated January 25, 2008

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

By: /s/ Rao Uppaluri

---

Name: Rao Uppaluri  
Title: Chief Financial Officer

Date January 25, 2008

---

Contacts:  
Corporate:  
Steven D. Rubin  
305 575-6000

Media:  
GendeLLindheim BioCom Partners  
Barbara Lindheim  
212 918-4650

## OPKO HEALTH ANNOUNCES CHANGES TO BOARD OF DIRECTORS

**MIAMI, FL - January 25, 2008-** OPKO Health, Inc. (AMEX: OPK) today announced the appointment of Thomas E. Beier and Richard C. Pfenniger, Jr. to its Board of Directors. The company also announced the resignation of former Board member David Eichler. Mr. Pfenniger was appointed to fill the vacancy created by Mr. Eichler's resignation while Mr. Beier is assuming a newly created Board position.

"The addition of Tom Beier and Rick Pfenniger to OPKO's Board of Directors ensures the company will continue to benefit from a knowledgeable board with diverse perspectives and experience," said Phillip Frost, M.D., Chairman and CEO of OPKO. "I look forward to working with Tom and Rick and the entire Board of Directors as we continue to aggressively pursue our research and development programs and advance the clinical testing of bevasiranib, our lead agent for age-related macular degeneration. We also want to thank Dave Eichler for his past contributions as a Board member of OPKO."

Richard C. Pfenniger, Jr. joins the Board as Chairman of OPKO's Audit Committee. Mr. Pfenniger currently serves as the Chairman, CEO and President of Continucare Corporation, a provider of primary physician and practice management services. Prior to Continucare, Mr. Pfenniger was CEO and Vice Chairman of Whitman Education Group, Inc. Previously, he was a Director of IVAX Corporation. Mr. Pfenniger currently is a Director of two other companies.

Thomas E. Beier will serve on OPKO's Audit and Compensation Committees. Mr. Beier currently is a Director of Ideation Acquisition Corp., a special purpose acquisition company formed for the purpose of acquiring businesses in digital media. Previously, he was Senior Vice President of Finance and Chief Financial Officer of IVAX Corporation. Before joining IVAX, Mr. Beier served as Executive Vice President and Chief Financial Officer of Intercontinental Bank.

OPKO's Board of Directors now includes ten members.

### About OPKO Health, Inc.

Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III trial after successfully completing Phase II trials for wet age-related macular degeneration and diabetic macular edema. OPKO is developing a preclinical pipeline of novel agents for ophthalmic diseases, and it markets innovative diagnostic imaging systems that complement the company's therapeutic products. For more information visit the company's website at [www.opko.com](http://www.opko.com).

*This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the potential benefits of bevasiranib, our ability to aggressively engage in R&D activities and advance clinical testing of bevasiranib and our ability to develop a preclinical pipeline of novel agents for ophthalmic diseases, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those factors described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that enrollment of patients for the Phase III clinical trial for bevasiranib, may not be successful, that the Phase III clinical trial itself may not be completed on a timely basis or at all, that any of our compounds under development, including bevasiranib, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.*

####

---